<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131132">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01913977</url>
  </required_header>
  <id_info>
    <org_study_id>2013/386</org_study_id>
    <nct_id>NCT01913977</nct_id>
  </id_info>
  <brief_title>Clinical Study to Determine the Optimal Operation Parameters During CO2 Removal With the Abylcap® System</brief_title>
  <official_title>Clinical Study to Determine the Optimal Operation Parameters During CO2 Removal With the Abylcap® System.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study includes 5 patients with ARDS (Acute Respiratory Distress Syndrome)
      treated by mechanical ventilation. In case of respiratory acidosis, extracorporeal CO2
      (carbon dioxide)removal might be necessary. We hereby work with the Abylcap system with the
      oxygenator Lilliput2 as CO2 remover (Bellco, Italy).

      The patients (M/V) are older than 18, not pregnant, have a BMI&lt;30, and no contraindication
      for anticoagulation therapy.

      Under standard conditions patients are treated with a blood flow of QB=300mL/min and a gas
      flow (100% 02) of QG=7L/min. Blood sampling is performed from the arterial bloodline in the
      patients at 0, 1h, 3h, 24h, 48h, 72h, 96h, and 120h.

      A parameter study is also performed to optimise CO2 removal. Herewith, blood samples (1mL)
      are taken from the inlet and outlet line of the Lilliput2 at the previously mentioned time
      points and for different flow setting: Blood flow (QB) 200-300-400mL/min and gas flow (QG)
      1.5, 3, 6, 7, 8L/min

      Blood samples are analysed for the different blood gases from which the extraction in the
      CO2 remover can be calculated for each setting of QB (blood flow) and QG (gas flow).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>calculation of CO2 extraction in blood samples during mechanical ventilation</measure>
    <time_frame>during mechanical ventilation with CO2 removal (max up to 120h)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Extraction is calculated from the relative difference in blood gases at the inlet and outlet of the CO2 remover.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Based on the extraction rates, the optimum parameter settings are derived</measure>
    <time_frame>During mechanical ventilation with CO2 removal (max up to 120h)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Extraction is calculated from the relative difference in blood gases at the inlet and outlet of the CO2 remover.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>ARDS (Acute Respiratory Distress Syndrome)</condition>
  <condition>Respiratory Acidosis</condition>
  <arm_group>
    <arm_group_label>Treatment with mechanical ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min</intervention_name>
    <description>Abylcap settings</description>
    <arm_group_label>Treatment with mechanical ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min</intervention_name>
    <description>Abylcap settings</description>
    <arm_group_label>Treatment with mechanical ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min</intervention_name>
    <description>Abylcap settings</description>
    <arm_group_label>Treatment with mechanical ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min</intervention_name>
    <description>Abylcap settings</description>
    <arm_group_label>Treatment with mechanical ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min</intervention_name>
    <description>Abylcap settings</description>
    <arm_group_label>Treatment with mechanical ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min</intervention_name>
    <description>Abylcap settings</description>
    <arm_group_label>Treatment with mechanical ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min</intervention_name>
    <description>Abylcap settings</description>
    <arm_group_label>Treatment with mechanical ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ARDS and respiratory acidosis on the intensive care unit

          -  Treated with the Abylcap system (Bellco, Italy)

          -  Not pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunny Eloot, PhD, MScBME, MScCivE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghent University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sunny Eloot, PhD, Engr.</last_name>
    <phone>+32 93321025</phone>
    <email>Sunny.Eloot@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunny Eloot, PhD, MScBME, MScCivE</last_name>
      <phone>+32 9 3321025</phone>
      <email>Sunny.Eloot@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Sunny Eloot, PhD, MScBME, MScCivE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 31, 2013</lastchanged_date>
  <firstreceived_date>June 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Acidosis, Respiratory</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
